The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease

Paddy Gillespie, Eamon O'Shea, Andrew W. Murphy, Mary C. Byrne, Molly Byrne, Susan M. Smith, Margaret E. Cupples, SPHERE Study Team

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)
238 Downloads (Pure)

Abstract

Objectives: The Secondary Prevention of Heart disEase in geneRal practicE (SPHERE) trial has recently reported. This study examines the cost-effectiveness of the SPHERE intervention in both healthcare systems on the island of Ireland.

Methods: Incremental cost-effectiveness analysis. A probabilistic model was developed to combine within-trial and beyond-trial impacts of treatment to estimate the lifetime costs and benefits of two secondary prevention strategies: Intervention - tailored practice and patient care plans; and Control - standardized usual care.

Results: The intervention strategy resulted in mean cost savings per patient of €512.77 (95 percent confidence interval [CI], −1086.46–91.98) and an increase in mean quality-adjusted life-years (QALYs) per patient of 0.0051 (95 percent CI, −0.0101–0.0200), when compared with the control strategy. The probability of the intervention being cost-effective was 94 percent if decision makers are willing to pay €45,000 per additional QALY.

Conclusions: Decision makers in both settings must determine whether the level of evidence presented is sufficient to justify the adoption of the SPHERE intervention in clinical practice.

Original languageEnglish
Pages (from-to)263-271
Number of pages9
JournalInternational Journal of Technology Assessment in Health Care
Volume26
Issue number3
Early online date29 Jun 2010
DOIs
Publication statusPublished - 01 Jul 2010

ASJC Scopus subject areas

  • Health Policy

Fingerprint

Dive into the research topics of 'The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease'. Together they form a unique fingerprint.

Cite this